Kidney Disease, End-Stage Clinical Trial
Official title:
A Prospective Single-Center, Open Label, Non-Randomized Study Evaluating the Use of the Qidni/D Hemodialysis System by Subjects With End-Stage Renal Disease
The main goal of this clinical study is to evaluate the safety of the Qidni/D Hemodialysis System in patients with end-stage renal disease. The main question it aims to answer is: Is the Qidni/D safe for performing hemodialysis? Participants will be subjected to one treatment of hemodialysis for up to 4 hours with the use of the Qidni/D.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT04665310 -
Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant
|
Phase 4 | |
| Completed |
NCT02964429 -
Determination In-vivo KUF for Diacap Pro Hemodialyser
|
N/A | |
| Recruiting |
NCT04634916 -
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
|
N/A | |
| Not yet recruiting |
NCT06089473 -
Virtual Home-based Physical Pre-habilitation in Kidney Transplant Candidates
|
N/A | |
| Completed |
NCT03149328 -
Electronic Patient-Reported Outcomes in Clinical Kidney Practice (ePRO Kidney)
|
N/A | |
| Active, not recruiting |
NCT04484220 -
Ellipsys Vascular Access System Post Market Surveillance (PS) Study
|
N/A |